ReviewAsia-Pacific journal of oncology nursing2024
Management of neurotoxic reactions induced by antibody-drug conjugates.
Review in Asia-Pacific journal of oncology nursing, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Understanding cachexia and muscle dysfunction in the context of metastatic breast cancer.Cancer metastasis reviews · 2026Review
- Toxicities of Antibody-Drug Conjugates in Breast Cancer: From Mechanistic Insights to Clinical Management.Pharmaceutics · 2026Review
- Awareness, attitudes, and self-reported clinical management of antimicrobial-associated neurocognitive adverse effects among healthcare providers in Saudi Arabia.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, many new antitumor drugs have been approved for clinical use. Among them, antibody-drug conjugates (ADCs) are an innovative drug group that combines the advantages of chemotherapy with a cytotoxic drug and targeted therapy with monoclonal antibodies. However, although ADCs provide survival benefits to patients, their special composition and mode of action also lead to specific adverse effects. Among the common adverse effects caused by ADCs, peripheral neuropathy (PN) affects patients' quality of life and also present significant challenges to clinical nursing. There are several guidelines and consensus for treating chemotherapy-induced peripheral neuropathy. However, there are no specific guidelines for managing PN caused by ADCs. Nurses play an important role in the prevention and management of PN, and their relevant knowledge and skills for symptom assessment, functional deficit screening, patient referral and advocacy, and patient education are indispensable. By combining Chinese and international guidelines, consensus, and related studies, this paper reviewed the occurrence and characteristics of ADC-induced PN and highlighted the principles of prevention, treatment, and nursing care to provide a reference for clinical nursing practice and improve the safety of ADCs for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.